Oncomed Pharma (OMED) Misses Q2 EPS by 50c

Oncomed Pharma (NASDAQ: OMED) reported Q2 EPS of ($0.53), $0.50 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $6 million versus the consensus estimate of $21.28 million.

For earnings history and earnings-related data on Oncomed Pharma (OMED) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c